Entera Bio (NASDAQ:ENTX) Director Sean Ellis Acquires 18,000 Shares

Entera Bio Ltd. (NASDAQ:ENTX) Director Sean Ellis acquired 18,000 shares of the business’s stock in a transaction on Monday, February 9th. The shares were purchased at an average price of $1.24 per share, for a total transaction of $22,320.00. Following the purchase, the director directly owned 178,098 shares of the company’s stock, valued at $220,841.52. This represents a 11.24% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Entera Bio Stock Up 9.7%

NASDAQ:ENTX traded up $0.14 during trading hours on Wednesday, reaching $1.59. 208,487 shares of the stock were exchanged, compared to its average volume of 274,594. The stock has a market capitalization of $72.92 million, a P/E ratio of -6.42 and a beta of 1.84. The firm has a 50 day simple moving average of $1.71 and a 200-day simple moving average of $2.03. Entera Bio Ltd. has a 52 week low of $1.00 and a 52 week high of $3.22.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. As a group, analysts expect that Entera Bio Ltd. will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ENTX. Citadel Advisors LLC increased its stake in shares of Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after purchasing an additional 28,322 shares during the period. HighTower Advisors LLC grew its holdings in Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares in the last quarter. Finally, Bessemer Group Inc. bought a new position in Entera Bio in the 2nd quarter worth approximately $268,000. Institutional investors own 14.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ENTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a research note on Saturday, December 27th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research note on Monday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Entera Bio currently has a consensus rating of “Hold” and a consensus target price of $10.00.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.